Biohacking Pioneer Hails Common Nasal Spray as Potential Longevity Key
Dave Asprey, the founder of the biohacking movement, has highlighted new research suggesting that oxymetazoline, the active ingredient in the over-the-counter nasal spray Afrin, could be repurposed for anti-aging therapies. While the drug is known for causing rebound congestion if used excessively, studies indicate it may improve cell-to-cell communication, a key factor in aging. Asprey argues that major longevity breakthroughs may come from existing medications rather than new molecules, though experts caution that human trials are still years away.
Key points
- Dave Asprey, a prominent figure in the biohacking community, shared on Instagram that oxymetazoline could be the next major longevity breakthrough, despite its reputation as a habit-forming decongestant.
- A study from Northeastern University screened 6,442 drugs to identify compounds that impact 11 biological 'hallmarks of aging,' including epigenetic alterations and protein clearance.
- The research identified oxymetazoline, found in Afrin and Sinex, as a potential candidate to improve intercellular communication, which degrades with age and affects immune function and muscle mass.
- Asprey emphasized that significant longevity gains might come from repurposing existing shelf-stable drugs rather than developing entirely new molecules.
- Aspirin was also flagged in the study for its potential impact on five hallmarks of aging, including the same intercellular communication pathway targeted by oxymetazoline.
- Researchers at Harvard are currently investigating the cellular mechanisms of oxymetazoline, but no human clinical trials are underway, and the drug is not yet considered a cure for aging.
Background
This development follows earlier coverage in July 2026 regarding a Northeastern University and Harvard Medical School framework that screened thousands of medications to identify potential anti-aging candidates. That initial report, published in Nature Aging, highlighted oxymetazoline and aspirin as promising repurposing targets but stressed that the findings provided a roadmap for future testing rather than immediate clinical solutions. The current news reflects the public interest generated by biohacking figures like Asprey, who often amplify early-stage scientific findings to the general public, despite the lack of human trial data.
Why it matters
The potential repurposing of affordable, over-the-counter medications like oxymetazoline for longevity could democratize access to anti-aging interventions if proven effective. However, the stark contrast between the drug's known side effects, such as rebound congestion, and its theoretical benefits highlights the complexity of drug repurposing. It also underscores the current state of longevity science, where computational screening identifies candidates, but rigorous human trials remain distant, preventing premature public adoption of unproven therapies.
What to watch
Researchers at Harvard are expected to continue investigating the specific cellular mechanisms by which oxymetazoline improves intercellular communication. Following these in-vitro and animal studies, the next critical step will be determining if the drug can be safely administered to humans for longevity purposes without triggering the adverse effects associated with its current use as a decongestant. No human trials are currently planned, and the timeline for such studies remains uncertain.
Want the full story? Read the original reporting
Read on New York Post